Fibroblast growth factor 21 (FGF21) has long been considered as a biomarker of NAFLD, and recent studies have shown the protective effect of FGF21 analogs on NAFLD. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.